Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Learn how natural strategies for managing blood sugar can improve your energy, mood, and metabolic health for long-term ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

The research sheds new light on how this enzyme influences glucagon secretion in pancreatic alpha (α) cells, a process crucial for maintaining healthy blood sugar levels. The research ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Dr. Will Bulsiewicz explains the importance of spacing meals apart to improve gut health, enhance digestion, and align with natural body rhythms.

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...